A YORK developer of regenerative medical devices has secured a European patent to cover use of its bladder repair technology.

Tissue Regenix, based at York Science Park, has been growing a global patent list to protect its dCELL technology, which removes DNA and other cellular material from animal and human tissue leaving a scaffold that can be applied to a patient’s body to repair diseased or worn-out body parts.

Working with its technology partner The University of Leeds to protect individual products and processes, Tissue Regenix's latest patent covering follows a recent announcement in May that a similar patent, related to tissue matrices for bladder implantation, has been granted in the United States.

Antony Odell, chief executive of Tissue Regenix said: "The global urology device market is one of the largest growth areas for the medical devices industry, and is estimated to be worth $8.6billion by 2022, driven by treatment demands for an ageing population.

“As part of the global roll-out of our dCELL technology, this latest European bladder patent adds to our ever-growing global portfolio, and helps Tissue Regenix achieve our aim of commercialising new ways to treat an array of urological disorders.”

Tissue Regenix has offices in the UK and US and is concentrated on the global commercialisation of its dCELL technology.

The company was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by partners around the world.